Diovan (Valsartan) Patent Expiration, LOE Window & CMS Spending

Diovan (Valsartan) by Novartis: Off-Patent Genericized (AB Competition), 16 AB generics, $24.3M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN021283 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors16
2024 CMS Total Public Spend$24.3M
2024 Medicare Part D Spend$20.7M
2024 Medicaid Spend$3.6M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 17.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.